CTCFL and non-small cell lung carcinoma: It has been reported that BORIS overexpression diminishes the DNA damage induced by cisplatin and is associated with a decreased overall survival rate in patients with NSCLC who have received cisplatin chemotherapy, suggesting that BORIS reduces cisplatin chemotherapy efficacy in NSCLC patients.